{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 55,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Spider plot (swimmer plot variant) showing individual patient response trajectories.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/46",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.55,
        "x": 0.03,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Spider plot of change in target lesion size from baseline over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4592949-64bf-4e2c-a31e-ea02f1e7e1ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.63,
        "y": 0.25
      },
      "kind": "list",
      "text": "Favourable 62.5% cORR, mPFS of 8.3 months across ITT; In CPS ≥5 cORR was 81.3% and mPFS was 11.1 months; 10% Grade ≥3 AEs related to rilvegostomig, 2.5% discontinuation rate",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1dc383f5-55da-4747-beba-96a3362d04d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. Data cut off: 4 July 2024. Treatment ongoing in 9 of 40 patients. Rivera Herrero F et al. Abstract 1422P presented at the European Society of Medical Oncology 2024. Collaboration partner: Compugen (rilvegostomig).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e41326c1-98ba-42e4-a00f-21ecde01ed58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "rilvegostomig – differentiated safety profile enables CTx combination in gastric and GEJ cancers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f9c376f-b9a1-4cd5-b1c6-c45bb0892e4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "title",
      "text": "Durable responses for rilvegostomig + CTx in locally advanced/metastatic gastric and GEJ cancers",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d45fabf9-1b9b-4b0a-8b6d-d3e128e9c924",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}